Abstract:High-throughput screening (HTS), as one of the key techniques in drug discovery, is frequently used to identify promising drug candidates in a largely automated and cost-effective way. One of the necessary conditions for successful HTS campaigns is a large and diverse compound library, enabling hundreds of thousands of activity measurements per project. Such collections of data hold great promise for computational and experimental drug discovery efforts, especially when leveraged in combination with modern deep learning techniques, and can potentially lead to improved drug activity predictions and cheaper and more effective experimental design. However, existing collections of machine-learning-ready public datasets do not exploit the multiple data modalities present in real-world HTS projects. Thus, the largest fraction of experimental measurements, corresponding to hundreds of thousands of "noisy" activity values from primary screening, are effectively ignored in the majority of machine learning models of HTS data. To address these limitations, we introduce Multifidelity PubChem BioAssay (MF-PCBA), a curated collection of 60 datasets that includes two data modalities for each dataset, corresponding to primary and confirmatory screening, an aspect that we call <i>multifidelity</i>. Multifidelity data accurately reflect real-world HTS conventions and present a new, challenging task for machine learning: the integration of low- and high-fidelity measurements through molecular representation learning, taking into account the orders-of-magnitude difference in size between the primary and confirmatory screens. Here we detail the steps taken to assemble MF-PCBA in terms of data acquisition from PubChem and the filtering steps required to curate the raw data. We also provide an evaluation of a recent deep-learning-based method for multifidelity integration across the introduced datasets, demonstrating the benefit of leveraging all HTS modalities, and a discussion in terms of the roughness of the molecular activity landscape. In total, MF-PCBA contains over 16.6 million unique molecule-protein interactions. The datasets can be easily assembled by using the source code available at https://github.com/davidbuterez/mf-pcba.

Identification of Compounds That Interfere with High‐Throughput Screening Assay Technologies

Machine Learning Assisted Hit Prioritization for High Throughput Screening in Drug Discovery

Tackling assay interference associated with small molecules

Prediction of compound-target interaction using several artificial intelligence algorithms and comparison with a consensus-based strategy

ChemFH: an integrated tool for screening frequent false positives in chemical biology and drug discovery

Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling

Computational Screening for Active Compounds Targeting Protein Sequences: Methodology and Experimental Validation

MF-PCBA: Multifidelity High-Throughput Screening Benchmarks for Drug Discovery and Machine Learning

Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening

High-Throughput Image-Based Assay for Identifying In Vitro Hepatocyte Microtubule Disruption

Compartmentalization of Enhanced Biomolecular Interactions for High-Throughput Drug Screening in Test Tubes

Developing and Validating Predictive Decision Tree Models from Mining Chemical Structural Fingerprints and High–throughput Screening Data in PubChem

PrePeP: A Tool for the Identification and Characterization of Pan Assay Interference Compounds

Unleashing high content screening in hit detection - Benchmarking AI workflows including novelty detection

Development of a Novel In Silico Classification Model to Assess Reactive Metabolite Formation in the Cysteine Trapping Assay and Investigation of Important Substructures

Prediction of Chemical-Protein Interactions: Multitarget-Qsar Versus Computational Chemogenomic Methods

Identifying Actives from HTS Data Sets: Practical Approaches for the Selection of an Appropriate HTS Data-Processing Method and Quality Control Review

Compound Activity Prediction with Dose-Dependent Transcriptomic Profiles and Deep Learning

Gains from no real PAINS: Where ‘Fair Trial Strategy’ stands in the development of multi-target ligands

Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning